Lam Research 10-Q 2026-09-27
LRCX · CIK 707549 · Form 10-Q · Period ended September 27, 2026 · Filed October 22, 2026
Revenue rose 54.4% to $8.22 billion. Operating margin was 40.0%, against 34.4% a year earlier. Net income was $2.75 billion.
8 sections, 213K characters. Original on sec.gov · ·
| Measure | Quarter ended Sep 27, 2026 | Quarter ended Sep 28, 2025 | Change |
|---|---|---|---|
| Revenue | $8.22B | $5.32B | +54.4% |
| Operating income | $3.28B | $1.83B | +79.5% |
| Net income | $2.75B | $1.57B | +75.5% |
| Diluted EPS | $2.19 | $1.24 | +76.6% |
| Free cash flow* | $3.24B | $1.59B | +103% |
| Cash and equivalents | $7.44B | n/a | n/a |
| Operating margin* | 40.0% | 34.4% | +5.6 pts |
From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.
Cover and table of contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 27, 2026
or
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 000-12933
LAM RESEARCH CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 94-2634797 | |||||||
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||
| 4650 Cushing Parkway, Fremont, California | 94538 | |||||||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (510) 572-0200
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Common Stock, Par Value $0.001 Per Share | LRCX | The Nasdaq Stock Market | ||||||
| (Nasdaq Global Select Market) |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☒ | Accelerated filer | ☐ | |||||||||||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||||||||||||||||
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of October 20, 2026, the Registrant had 1,249,171 thousand shares of Common Stock outstanding.
LAM RESEARCH CORPORATION
TABLE OF CONTENTS
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (“Form 10-Q”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this report are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “anticipate,” “assume,” “become,” “believe,” “can,” “commit,” “continue,” “could,” “depend,” “drive,” “estimate,” “expect,” “focus,” “forecast,” “future,” “goal,” “grow,” “increase,” “intend,” “likely,” “maintain,” “may,” “objective,” “ongoing,” “opportunity,” “plan,” “possible,” “potential,” “predict,” “probable,” “project,” “remain,” “require,” “seek,” “should,” “strategy,” “sustain,” “target,” “transition,” “will,” “would,” or variations of these words or other similar expressions. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements in this report include, but are not limited to, statements concerning: our future results of operations and financial condition; our commitment to driving semiconductor breakthroughs; trends related to demand for electronic systems, including for high performance, energy efficient and highly integrated semiconductor devices, semiconductor manufacturer adoption of vertical scaling and advanced integration approaches, technology inflections, including increasing manufacturing complexity and precision requirements, and demand for our technologies and services; our belief regarding our position in deposition, etch, and clean markets and perceived opportunities for sustainable differentiation for us due to several specified factors; our research and development strategy, and beliefs and expectations regarding perceived opportunities and continued investments in research and development; our stock repurchase program, including the performance of the September 2026 ASRs and the available amount under the program for repurchase, our capital allocation strategy, including our intention to pay quarterly dividends, our focus to return a portion of our free cash flow to stockholders over time through dividends and share repurchases, and expected sources of funds for capital return activities; continued growth of wafer fabrication investment in calendar year 2026, including the role of the artificial intelligence (“AI”) market in driving higher spending across both the memory and non-memory market segments; our belief regarding demand for semiconductors and technology inflections in the semiconductor industry driving sustainable growth and increasing market opportunities for our products and services in the deposition, etch, and clean businesses; customer investments driving demand for our products and services; beliefs, estimates, and assumptions relating to our significant accounting policies, including with respect to revenue recognition, inventory valuation, and income taxes; our expectations regarding the sufficiency of our liquidity to support our anticipated business activities through the next twelve months based on anticipated cash flows and our current business outlook; our ability to access the capital markets; the dependence of our liquidity on our future revenues and ability to manage costs; expectations regarding deferred revenue; our evaluation of uncertain tax positions and related effects if recognized; financial instruments and related fair value estimates and assumptions, and credit concentration risks; commitments and contingencies, including our beliefs regarding the materiality of legal proceedings and probability of a material loss; and other statements included in Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” Part II, Item 1A, “Risk Factors,” and elsewhere in this Form 10-Q.
These forward-looking statements are not a guarantee of future performance and involve a number of risks, uncertainties, and other factors that could cause our actual results or outcomes, or the timing of our results or outcomes, to differ materially from those expressed or implied in this Form 10-Q. Such risks, uncertainties, and other factors include, among others, the following:
-
our assumptions related to continued expansion of the wafer fabrication equipment market, growth of deposition and etch intensity, and scaling of our operations may prove invalid;
-
business, economic, political, and/or regulatory conditions in the consumer electronics industry, the semiconductor industry and the overall economy, including wafer fabrication equipment spending or demand related to artificial intelligence (“AI”), may deteriorate or change;
-
the actions, performance, or investment levels of our customers and competitors may be inconsistent with our expectations;
-
customer and product mix, including across market segments and geographical regions, may change;
-
we may be unable to realize the value of our products and technology, successfully commercialize new products and technologies, implement pricing initiatives, or execute on perceived opportunities;
-
we may be unable to achieve anticipated operational, manufacturing, supply chain, procurement, and scale efficiencies;
-
customer technology transitions, capacity expansions, and fab construction projects may have different timing or be less successful than we expect;
-
we may be unable to manage operating expenses effectively while continuing to invest in research and development (“R&D”), product innovation, customer support, and future growth opportunities;
-
trade regulations, export controls (including entity listings, end use/user controls, technology controls, and foreign direct product rules), tariffs, trade disputes, and other geopolitical developments may inhibit our ability to sell our products or services;
-
supply chain cost increases, tariffs, and other inflationary pressures may continue to impact our profitability;
-
supply chain disruptions or manufacturing capacity constraints may limit our ability to manufacture and sell our products;
-
natural and human-caused disasters, disease outbreaks, war, terrorism, political or governmental unrest or instability, or other events beyond our control may impact our operations and revenue in affected areas; and
-
the other factors described in Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Part II, Item 1A, “Risk Factors” of this Form 10-Q and other documents we file from time to time with the Securities and Exchange Commission (“SEC”).
You should evaluate all forward-looking statements made in this Form 10-Q in the context of these risks, uncertainties, and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and are based on our current beliefs, expectations, and assumptions about future events. Except as required by law, we do not undertake any obligation to revise or update these forward-looking statements as a result of events or circumstances that occur after the date of this report or to reflect the occurrence or effect of anticipated or unanticipated events.
Lam Research Corporation 2027 Q1 10-Q 3
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
LAM RESEARCH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
| Three Months Ended | |||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | ||||||||||||||||||||||
| Revenue | $ | 8,219,418 | $ | 5,324,173 | |||||||||||||||||||
| Cost of goods sold | 3,920,565 | 2,639,294 | |||||||||||||||||||||
| Gross margin | 4,298,853 | 2,684,879 | |||||||||||||||||||||
| Research and development | 666,398 | 576,446 | |||||||||||||||||||||
| Selling, general, and administrative | 348,728 | 279,345 | |||||||||||||||||||||
| Total operating expenses | 1,015,126 | 855,791 | |||||||||||||||||||||
| Operating income | 3,283,727 | 1,829,088 | |||||||||||||||||||||
| Other income (expense), net | 28,493 | 30,074 | |||||||||||||||||||||
| Income before income taxes | 3,312,220 | 1,859,162 | |||||||||||||||||||||
| Income tax expense | (559,082) | (290,502) | |||||||||||||||||||||
| Net income | $ | 2,753,138 | $ | 1,568,660 | |||||||||||||||||||
| Net income per share: | |||||||||||||||||||||||
| Basic | $ | 2.20 | $ | 1.24 | |||||||||||||||||||
| Diluted | $ | 2.19 | $ | 1.24 | |||||||||||||||||||
| Number of shares used in per share calculations: | |||||||||||||||||||||||
| Basic | 1,250,883 | 1,264,446 | |||||||||||||||||||||
| Diluted | 1,255,768 | 1,269,313 | |||||||||||||||||||||
See Notes to Condensed Consolidated Financial Statements
Lam Research Corporation 2027 Q1 10-Q 4
LAM RESEARCH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in thousands)
(unaudited)
| Three Months Ended | |||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | ||||||||||||||||||||||
| Net income | $ | 2,753,138 | $ | 1,568,660 | |||||||||||||||||||
| Other comprehensive income (loss), net of tax: | |||||||||||||||||||||||
| Foreign currency translation adjustment | 9,829 | (12,726) | |||||||||||||||||||||
| Cash flow hedges: | |||||||||||||||||||||||
| Net unrealized (losses) gains during the period | (3,695) | 8,570 | |||||||||||||||||||||
| Net gains reclassified into net income | (6,421) | (7,095) | |||||||||||||||||||||
| (10,116) | 1,475 | ||||||||||||||||||||||
| Defined benefit plans, net change in unrealized component | 90 | 83 | |||||||||||||||||||||
| Other comprehensive income (loss), net of tax | (197) | (11,168) | |||||||||||||||||||||
| Comprehensive income | $ | 2,752,941 | $ | 1,557,492 | |||||||||||||||||||
See Notes to Condensed Consolidated Financial Statements
Lam Research Corporation 2027 Q1 10-Q 5
LAM RESEARCH CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)
| September 27, 2026 | June 28, 2026 | ||||||||||
| (unaudited) | (1) | ||||||||||
| ASSETS | |||||||||||
| Cash and cash equivalents | $ | 7,437,384 | $ | 5,579,171 | |||||||
| Accounts receivable, less allowance of $8,358 as of September 27, 2026, and $8,071 as of June 28, 2026 | 5,658,379 | 5,339,682 | |||||||||
| Inventories | 4,550,544 | 4,276,111 | |||||||||
| Prepaid expenses and other current assets | 477,805 | 415,741 | |||||||||
| Total current assets | 18,124,112 | 15,610,705 | |||||||||
| Property and equipment, net | 3,126,029 | 2,956,472 | |||||||||
| Goodwill and intangible assets, net | 1,911,547 | 1,895,859 | |||||||||
| Other assets | 3,191,368 | 3,066,707 | |||||||||
| Total assets | $ | 26,353,056 | $ | 23,529,743 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Trade accounts payable | $ | 1,592,208 | $ | 1,302,467 | |||||||
| Accrued expenses and other current liabilities | 3,287,463 | 2,351,541 | |||||||||
| Deferred profit | 2,429,342 | 2,279,168 | |||||||||
| Current portion of long-term debt and finance lease obligations | 3,486 | 4,073 | |||||||||
| Total current liabilities | 7,312,499 | 5,937,249 | |||||||||
| Long-term debt and finance lease obligations | 3,731,958 | 3,730,490 | |||||||||
| Income taxes payable | 684,273 | 681,197 | |||||||||
| Other long-term liabilities | 715,852 | 709,886 | |||||||||
| Total liabilities | 12,444,582 | 11,058,822 | |||||||||
| Commitments and contingencies (refer to Note 12) | |||||||||||
| Stockholders’ equity: | |||||||||||
| Preferred stock, at par value of $0.001 per share; authorized, 5,000 shares, none outstanding | — | — | |||||||||
| Common stock, at par value of $0.001 per share; authorized, 4,000,000 shares as of September 27, 2026 and June 28, 2026; issued and outstanding, 1,249,145 shares as of September 27, 2026, and 1,251,278 shares as of June 28, 2026 | 1,249 | 1,251 | |||||||||
| Additional paid-in capital | 9,363,408 | 9,244,449 | |||||||||
| Treasury stock, at cost; 1,712,490 shares as of September 27, 2026, and 1,710,109 shares as of June 28, 2026 | (32,620,072) | (31,597,945) | |||||||||
| Accumulated other comprehensive loss | (127,285) | (127,088) | |||||||||
| Retained earnings | 37,291,174 | 34,950,254 | |||||||||
| Total stockholders’ equity | 13,908,474 | 12,470,921 | |||||||||
| Total liabilities and stockholders’ equity | $ | 26,353,056 | $ | 23,529,743 | |||||||
(1)Derived from audited financial statements
See Notes to Condensed Consolidated Financial Statements
Lam Research Corporation 2027 Q1 10-Q 6
LAM RESEARCH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
| Three Months Ended | |||||||||||
| September 27, 2026 | September 28, 2025 | ||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||||||
| Net income | $ | 2,753,138 | $ | 1,568,660 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization | 122,072 | 101,644 | |||||||||
| Deferred income taxes | (55,300) | (62,875) | |||||||||
| Equity-based compensation expense | 114,696 | 97,241 | |||||||||
| Other, net | 27,633 | (1,890) | |||||||||
| Changes in operating assets and liabilities | 535,413 | 76,184 | |||||||||
| Net cash provided by operating activities | 3,497,652 | 1,778,964 | |||||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||||||
| Capital expenditures and intangible assets | (257,697) | (185,121) | |||||||||
| Other, net | (9,292) | (927) | |||||||||
| Net cash used for investing activities | (266,989) | (186,048) | |||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||||||
| Principal payments on debt, including finance lease obligations and payments for debt issuance costs | (34,489) | (1,417) | |||||||||
| Treasury stock purchases, including excise tax payments | (1,024,965) | (975,791) | |||||||||
| Dividends paid | (325,402) | (291,981) | |||||||||
| Proceeds from issuance of common stock, net of issuance costs | 4,263 | — | |||||||||
| Other, net | (1,786) | (12,449) | |||||||||
| Net cash used for financing activities | (1,382,379) | (1,281,638) | |||||||||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 4,663 | (7,059) | |||||||||
| Net change in cash, cash equivalents, and restricted cash | 1,852,947 | 304,219 | |||||||||
| Cash, cash equivalents, and restricted cash at beginning of period (1) | 5,597,943 | 6,407,656 | |||||||||
| Cash, cash equivalents, and restricted cash at end of period (1) | $ | 7,450,890 | $ | 6,711,875 | |||||||
| Schedule of non-cash transactions: | |||||||||||
| Accrued payables for stock repurchases, including applicable excise tax | $ | 31,512 | $ | 58,827 | |||||||
| Accrued payables for capital expenditures | 141,965 | 95,745 | |||||||||
| Dividends payable | 412,218 | 327,507 | |||||||||
| Transfers of finished goods inventory to property and equipment | 37,053 | 22,897 | |||||||||
| Reconciliation of cash, cash equivalents, and restricted cash | September 27, 2026 | September 28, 2025 | |||||||||
| Cash and cash equivalents | $ | 7,437,384 | $ | 6,693,046 | |||||||
| Restricted cash and cash equivalents (1) | 13,506 | 18,829 | |||||||||
| Total cash, cash equivalents, and restricted cash | $ | 7,450,890 | $ | 6,711,875 | |||||||
(1)Restricted cash is reported within Other assets in the Condensed Consolidated Balance Sheets
See Notes to Condensed Consolidated Financial Statements
Lam Research Corporation 2027 Q1 10-Q 7
LAM RESEARCH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands)
(unaudited)
| Three Months Ended | |||||||||||||||||||||||||||||||||||||||||
| September 27, 2026 | |||||||||||||||||||||||||||||||||||||||||
| Common Stock Shares | Common Stock | Additional Paid-in Capital | Treasury Stock | Accumulated Other Comprehensive Loss | Retained Earnings | Total | |||||||||||||||||||||||||||||||||||
| Balance at June 28, 2026 | 1,251,278 | $ | 1,251 | $ | 9,244,449 | $ | (31,597,945) | $ | (127,088) | $ | 34,950,254 | $ | 12,470,921 | ||||||||||||||||||||||||||||
| Issuance of common stock | 248 | — | 4,263 | — | — | — | 4,263 | ||||||||||||||||||||||||||||||||||
| Purchase of treasury stock | (2,381) | (2) | — | (1,022,127) | — | — | (1,022,129) | ||||||||||||||||||||||||||||||||||
| Equity-based compensation expense | — | — | 114,696 | — | — | — | 114,696 | ||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | 2,753,138 | 2,753,138 | ||||||||||||||||||||||||||||||||||
| Other comprehensive loss | — | — | — | — | (197) | — | (197) | ||||||||||||||||||||||||||||||||||
| Cash dividends declared ($0.33 per common share) | — | — | — | — | — | (412,218) | (412,218) | ||||||||||||||||||||||||||||||||||
| Balance at September 27, 2026 | 1,249,145 | $ | 1,249 | $ | 9,363,408 | $ | (32,620,072) | $ | (127,285) | $ | 37,291,174 | $ | 13,908,474 | ||||||||||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||||||||||||||||||||
| September 28, 2025 | |||||||||||||||||||||||||||||||||||||||||
| Common Stock Shares | Common Stock | Additional Paid-in Capital | Treasury Stock | Accumulated Other Comprehensive Loss | Retained Earnings | Total | |||||||||||||||||||||||||||||||||||
| Balance at June 29, 2025 | 1,268,740 | $ | 1,268 | $ | 8,697,290 | $ | (27,763,430) | $ | (62,423) | $ | 28,988,914 | $ | 9,861,619 | ||||||||||||||||||||||||||||
| Issuance of common stock | 178 | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Purchase of treasury stock | (9,742) | (10) | — | (996,083) | — | — | (996,093) | ||||||||||||||||||||||||||||||||||
| Equity-based compensation expense | — | — | 97,241 | — | — | — | 97,241 | ||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | 1,568,660 | 1,568,660 | ||||||||||||||||||||||||||||||||||
| Other comprehensive loss | — | — | — | — | (11,168) | — | (11,168) | ||||||||||||||||||||||||||||||||||
| Cash dividends declared ($0.26 per common share) | — | — | — | — | — | (327,507) | (327,507) | ||||||||||||||||||||||||||||||||||
| Balance at September 28, 2025 | 1,259,176 | $ | 1,258 | $ | 8,794,531 | $ | (28,759,513) | $ | (73,591) | $ | 30,230,067 | $ | 10,192,752 | ||||||||||||||||||||||||||||
See Notes to Condensed Consolidated Financial Statements
Lam Research Corporation 2027 Q1 10-Q 8
LAM RESEARCH CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 27, 2026
(Unaudited)
NOTE 1 — BASIS OF PRESENTATION
The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the periods presented have been included. The accompanying unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements of Lam Research Corporation (“Lam Research” or the “Company”) for the fiscal year ended June 28, 2026, which are included in the Company’s Annual Report on Form 10-K as of and for the year ended June 28, 2026 (the “2026 Form 10-K”).
The Condensed Consolidated Financial Statements include the accounts of Lam Research and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company’s reporting period is a 52/53-week fiscal year. The Company’s current fiscal year will end June 27, 2027 and includes 52 weeks. The quarters ended September 27, 2026 and September 28, 2025 included 13 weeks.
NOTE 2 — RECENT ACCOUNTING PRONOUNCEMENTS
Recently Adopted or Effective
The Company has not adopted any new accounting standards during the three months ended September 27, 2026 that have a material impact on the Company’s Condensed Consolidated Financial Statements.
NOTE 3 — REVENUE
Disaggregation of Revenue
The Company operates in seven geographic regions: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. For geographical reporting, revenue is attributed to the geographic location in which the customers’ facilities are located. The Company serves three primary markets: memory, foundry, and logic/integrated device manufacturing.
The following table presents the Company’s revenues disaggregated between systems and customer support-related revenue:
| Three Months Ended | |||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | ||||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Systems revenue | $ | 5,732,907 | $ | 3,547,565 | |||||||||||||||||||
| Customer support-related revenue and other | 2,486,511 | 1,776,608 | |||||||||||||||||||||
| $ | 8,219,418 | $ | 5,324,173 | ||||||||||||||||||||
Systems revenue includes sales of new leading-edge equipment in deposition, etch, clean and other wafer fabrication markets.
Customer support-related revenue includes sales of customer services, spares, upgrades, and non-leading-edge equipment from the Company’s Reliant® product line.
Lam Research Corporation 2027 Q1 10-Q 9
The following table presents the Company’s revenues disaggregated by geographic region:
| Three Months Ended | |||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | ||||||||||||||||||||||
| Revenue: | (in thousands) | ||||||||||||||||||||||
| China | $ | 2,885,608 | $ | 2,282,573 | |||||||||||||||||||
| Korea | 1,634,115 | 776,301 | |||||||||||||||||||||
| Taiwan | 1,482,087 | 1,027,214 | |||||||||||||||||||||
| Japan | 721,509 | 529,297 | |||||||||||||||||||||
| United States | 663,102 | 304,716 | |||||||||||||||||||||
| Southeast Asia | 531,694 | 302,254 | |||||||||||||||||||||
| Europe | 301,303 | 101,818 | |||||||||||||||||||||
| $ | 8,219,418 | $ | 5,324,173 | ||||||||||||||||||||
The following table presents the percentages of leading- and non-leading-edge equipment and upgrade revenue to each of the primary markets the Company serves:
| Three Months Ended | |||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | ||||||||||||||||||||||
| Foundry | 46 | % | 60 | % | |||||||||||||||||||
| Memory | 46 | % | 34 | % | |||||||||||||||||||
| Logic/integrated device manufacturing | 8 | % | 6 | % |
Deferred Revenue
Revenue of $901.2 million included in deferred profit at June 28, 2026 was recognized during the three months ended September 27, 2026, representing 37% of the $2.43 billion of deferred revenue as of June 28, 2026.
The following table summarizes the transaction price for contracts that have not yet been recognized as revenue as of September 27, 2026 and when the Company expects to recognize the amounts as revenue:
| Less than 1 Year | 1-3 Years | More than 3 Years | Total | ||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Deferred revenue | $ | 2,026,932 | $ | 539,916 | (1) | $ | 94,383 | (1) | $ | 2,661,231 | |||||||||||||
(1)This amount is reported in Deferred profit on the Company's Condensed Consolidated Balance Sheets as the customers can demand the performance to be satisfied at any time.
NOTE 4 — EQUITY-BASED COMPENSATION PLANS
The Lam Research Corporation 2015 Stock Incentive Plan, as amended, and the Lam Research Corporation 2025 Stock Incentive Plan provide for the grant of non-qualified equity-based awards of the Company’s Common Stock to eligible employees and non-employee directors, including stock options, restricted stock units (“RSUs”), and market-based performance RSUs (“market-based PRSUs”). An option is a right to purchase Common Stock at a set price. An RSU award is an agreement to issue a set number of shares of Common Stock at the time of vesting. The Company’s market-based PRSUs contain both a market condition and a service condition. The Company’s option, RSU, and market-based PRSU awards typically vest over a period of three years. The Company also has an employee stock purchase plan that allows eligible employees to purchase its Common Stock at a discount through payroll deductions.
The Company recognized the following equity-based compensation expense (including expense related to the employee stock purchase plan) in the Condensed Consolidated Statements of Operations:
| Three Months Ended | |||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | ||||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Equity-based compensation expense | $ | 114,696 | $ | 97,241 | |||||||||||||||||||
Lam Research Corporation 2027 Q1 10-Q 10
NOTE 5 — OTHER INCOME (EXPENSE), NET
The significant components of other income (expense), net, are as follows:
| Three Months Ended | |||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | ||||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Interest income | $ | 49,849 | $ | 63,930 | |||||||||||||||||||
| Interest expense | (36,762) | (42,472) | |||||||||||||||||||||
| Gains on deferred compensation plan-related assets, net | 12,870 | 23,088 | |||||||||||||||||||||
| Foreign exchange gains (losses), net | 3,889 | (5,534) | |||||||||||||||||||||
| Other, net | (1,353) | (8,938) | |||||||||||||||||||||
| $ | 28,493 | $ | 30,074 | ||||||||||||||||||||
NOTE 6 — INCOME TAX EXPENSE
The Company’s provision for income taxes and effective tax rate are as follows:
| Three Months Ended | |||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | ||||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Income tax expense | $ | 559,082 | $ | 290,502 | |||||||||||||||||||
| Effective tax rate | 16.9 | % | 15.6 | % |
The difference between the U.S. federal statutory tax rate of 21% and the Company’s effective tax rate for the three months ended September 27, 2026, and September 28, 2025, was primarily due to income in lower tax jurisdictions.
NOTE 7 — NET INCOME PER SHARE
Basic net income per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is computed using the treasury stock method, for dilutive stock options, and restricted stock units. The following table reconciles the inputs to the basic and diluted computations for net income per share.
| Three Months Ended | |||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | ||||||||||||||||||||||
| (in thousands, except per share data) | |||||||||||||||||||||||
| Numerator: | |||||||||||||||||||||||
| Net income | $ | 2,753,138 | $ | 1,568,660 | |||||||||||||||||||
| Denominator: | |||||||||||||||||||||||
| Basic average shares outstanding | 1,250,883 | 1,264,446 | |||||||||||||||||||||
| Effect of potential dilutive securities: | |||||||||||||||||||||||
| Employee stock plans | 4,885 | 4,867 | |||||||||||||||||||||
| Diluted average shares outstanding | 1,255,768 | 1,269,313 | |||||||||||||||||||||
| Net income per share - basic | $ | 2.20 | $ | 1.24 | |||||||||||||||||||
| Net income per share - diluted | $ | 2.19 | $ | 1.24 | |||||||||||||||||||
For purposes of computing diluted net income per share, weighted-average shares of common stock do not include potentially dilutive securities that are anti-dilutive under the treasury stock method. These anti-dilutive securities, including options and RSUs, were not material for the three months ended September 27, 2026 and September 28, 2025.
Lam Research Corporation 2027 Q1 10-Q 11
NOTE 8 — FINANCIAL INSTRUMENTS
There have been no material changes to the Company’s investment strategies and investment and fair value policies to those disclosed in Note 9, “Financial Instruments,” to the Consolidated Financial Statements in Part II, Item 8 of its 2026 Form 10-K. As of September 27, 2026 and June 28, 2026, the fair values of mutual funds and equity investments were not material. The Company had no debt security investments as of September 27, 2026 and June 28, 2026. The financial statement impacts to the Condensed Consolidated Statement of Operations from debt and equity investments were not material as of and for the three months ended September 27, 2026 and September 28, 2025.
The financial instruments reported within Cash and Cash Equivalents in the Company’s Condensed Consolidated Balance Sheets as of September 27, 2026, and June 28, 2026 consisted of the following:
| September 27, 2026 | June 28, 2026 | ||||||||||
| (in thousands) | |||||||||||
| Money market funds (fair value measured on a recurring basis, level 1) | $ | 3,270,420 | $ | 2,015,275 | |||||||
| Cash | 2,037,593 | 2,071,271 | |||||||||
| Time deposits | 2,129,371 | 1,492,625 | |||||||||
| $ | 7,437,384 | $ | 5,579,171 | ||||||||
Derivative Instruments and Hedging
There have been no material changes to the Company’s hedging strategies and policies to those disclosed in Note 9, “Financial Instruments,” to the Consolidated Financial Statements in Part II, Item 8 of its 2026 Form 10-K. As of September 27, 2026 and June 28, 2026, the fair value of outstanding cash flow and balance sheet hedges were not material. The financial statement impacts to the Condensed Consolidated Statement of Operations from derivative instruments and hedging activities were not material as of and for the three months ended September 27, 2026 and September 28, 2025.
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk and the Company’s mitigation strategies are materially the same as those disclosed in Note 9, “Financial Instruments,” to the Consolidated Financial Statements in Part II, Item 8 of its 2026 Form 10-K.
NOTE 9 — INVENTORIES
Inventories are stated at the lower of cost or net realizable value using standard costs that approximate actual costs on a first-in, first-out basis. Inventories consist of the following:
| September 27, 2026 | June 28, 2026 | ||||||||||
| (in thousands) | |||||||||||
| Raw materials | $ | 2,837,122 | $ | 2,551,150 | |||||||
| Work-in-process | 432,082 | 449,669 | |||||||||
| Finished goods | 1,281,340 | 1,275,292 | |||||||||
| $ | 4,550,544 | $ | 4,276,111 | ||||||||
Lam Research Corporation 2027 Q1 10-Q 12
NOTE 10 — PROPERTY AND EQUIPMENT, NET
Property and equipment, net is presented in the table below:
| September 27, 2026 | June 28, 2026 | ||||||||||
| (in thousands) | |||||||||||
| Manufacturing and engineering equipment | $ | 2,648,558 | $ | 2,559,970 | |||||||
| Buildings and improvements | 2,418,628 | 2,289,208 | |||||||||
| Computer and computer-related equipment | 201,551 | 192,354 | |||||||||
| Land | 268,471 | 264,507 | |||||||||
| Office equipment, furniture and fixtures | 123,176 | 114,797 | |||||||||
| 5,660,384 | 5,420,836 | ||||||||||
| Less: accumulated depreciation and amortization | $ | (2,583,166) | $ | (2,484,833) | |||||||
| $ | 3,077,218 | $ | 2,936,003 | ||||||||
The Company has excluded immaterial right-of-use assets, under finance leases, recorded within property and equipment, net from the table above.
NOTE 11 — ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consist of the following:
| September 27, 2026 | June 28, 2026 | ||||||||||
| (in thousands) | |||||||||||
| Accrued compensation | $ | 867,435 | $ | 695,498 | |||||||
| Warranty reserves | 320,689 | 270,044 | |||||||||
| Income and other taxes payable | 800,781 | 263,205 | |||||||||
| Dividends payable | 412,218 | 325,402 | |||||||||
| Other | 886,340 | 797,392 | |||||||||
| $ | 3,287,463 | $ | 2,351,541 | ||||||||
NOTE 12 — COMMITMENTS AND CONTINGENCIES
Guarantees
The Company has issued certain indemnifications to its lessors for taxes and general liability under some of its agreements. The Company has entered into insurance contracts that are intended to limit its exposure to such indemnifications. As of September 27, 2026, the Company had not recorded any liability on its Condensed Consolidated Financial Statements in connection with these indemnifications, as it does not believe, based on historical experience and information currently available, that it is probable that any material amounts will be paid under these guarantees.
Generally, the Company indemnifies, under pre-determined conditions and limitations, its customers for infringement of third-party intellectual property rights by the Company’s products or services. The Company seeks to limit its liability for such indemnity to an amount not to exceed the sales price of the products or services subject to its indemnification obligations. The Company does not believe, based on historical experience and information currently available, that it is probable that any material amounts will be paid under these guarantees.
The Company provides guarantees and standby letters of credit to certain parties as required for certain transactions initiated during the ordinary course of business. As of September 27, 2026, the maximum potential amount of future payments that the Company could be required to make under these arrangements and letters of credit was $290.3 million. The Company does not believe, based on historical experience and information currently available, that it is probable that any material amounts will be required to be paid.
In addition, the Company has entered into indemnification agreements with its directors, officers, and certain other employees, consistent with its Bylaws and Certificate of Incorporation; and under local law, the Company may be required to provide indemnification to its employees for actions within the scope of their employment. Although the Company maintains insurance contracts that cover some of the potential liability associated with these indemnification agreements, there is no guarantee that all such liabilities will be covered. The Company does not believe, based on historical experience and information currently available,
Lam Research Corporation 2027 Q1 10-Q 13
that it is probable that any material amounts will be required to be paid under such indemnification agreements or statutory obligations.
Warranties
The Company provides standard warranties on its systems. The liability amount is based on actual historical warranty spending activity by type of system, customer, and geographic region, modified for any known differences such as the impact of system reliability improvements. As of September 27, 2026, warranty reserves totaling $21.5 million were reported in Other long-term liabilities, and the remainder were included in Accrued expenses and other current liabilities in the Company’s Condensed Consolidated Balance Sheets.
Changes in the Company’s product warranty reserves were as follows:
| Three Months Ended | |||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | ||||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Balance at beginning of period | $ | 289,713 | $ | 265,466 | |||||||||||||||||||
| Warranties issued during the period | 124,600 | 65,584 | |||||||||||||||||||||
| Settlements made during the period | (57,078) | (64,525) | |||||||||||||||||||||
| Changes in liability for pre-existing warranties | (15,002) | (8,659) | |||||||||||||||||||||
| Balance at end of period | $ | 342,233 | $ | 257,866 | |||||||||||||||||||
Legal Proceedings
While the Company is not currently a party to any legal proceedings that it believes material, the Company is either a defendant or plaintiff in various actions that have arisen from time to time in the normal course of business, including intellectual property claims. The Company accrues for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. Based on current information, the Company does not believe that a material loss from known matters is probable and therefore has not recorded an accrual of any material amount for litigation or other contingencies related to existing legal proceedings.
NOTE 13 — STOCK REPURCHASE PROGRAM
In May 2024, the Board of Directors authorized the Company to repurchase up to an additional $10.00 billion of Common Stock; this authorization supplements the remaining balance from any prior authorizations. These repurchases can be conducted on the open market or as private purchases and may include the use of derivative contracts with large financial institutions, in all cases subject to compliance with applicable law. This repurchase program has no termination date and may be suspended or discontinued at any time.
Repurchases under the repurchase program were as follows during the periods indicated.
| Period | Total Number of Shares Repurchased | Total Cost of Repurchase (1) | Average Price Paid per Share (1,2) | Amount Available Under Repurchase Program | |||||||||||||||||||
| (in thousands, except per share data) | |||||||||||||||||||||||
| Available balance as of June 28, 2026 | $ | 4,042,724 | |||||||||||||||||||||
| Quarter ended September 27, 2026 | 2,344 | (3) | $ | 1,010,711 | $ | 329.17 | $ | 3,032,013 | |||||||||||||||
(1) The Company’s net share repurchases are subject to a 1% excise tax under the Inflation Reduction Act. Excise tax incurred reduces the amount available under the repurchase program, as applicable, and is included in the cost of shares repurchased in the Condensed Consolidated Statement of Stockholders’ Equity and the calculation of the average price paid per share.
(2) Average price paid per share excludes the effect of accelerated share repurchase activities. See additional disclosure below regarding the Company’s accelerated share repurchase activity during the fiscal year.
(3) Includes shares received at initial or final settlement of accelerated share repurchase agreements. See additional disclosure below regarding the Company’s accelerated share repurchase activity during the fiscal year.
Accelerated Share Repurchase Agreements
During the three months ended September 27, 2026, the Company entered into accelerated share repurchase agreements (the “September 2026 ASRs”) with two financial institutions to repurchase a total of $1.00 billion of Common Stock. The Company took an initial delivery of approximately 2.3 million shares, which represented 75% of the prepayment amount divided by the Company’s
Lam Research Corporation 2027 Q1 10-Q 14
closing stock price on the date of execution. The total number of shares to be received under the September 2026 ASRs will be based upon the average daily volume weighted average price of the Company’s Common Stock during the repurchase period, less an agreed upon discount. The September 2026 ASRs are expected to fully settle in the quarter ended December 27, 2026.
The Company recorded each of the September 2026 ASRs as equity transactions; as such, at the time of receipt, shares were included in treasury stock at fair market value as of the corresponding trade date. The Company reflects shares received as a repurchase of common stock in the weighted average shares of common stock outstanding calculation for basic and diluted earnings per share.
NOTE 14 — SEGMENT REPORTING
The Company operates in one reportable business segment: manufacturing and servicing of wafer processing semiconductor manufacturing equipment. The Company’s material operating segments qualify for aggregation due to their customer base and similarities in economic characteristics, nature of products and services, and processes for procurement, manufacturing, and distribution.
Segment information is prepared and managed on the same basis as described in Note 19, “Segment, Geographic Information, and Major Customers,” to the Consolidated Financial Statements in Part II, Item 8 of the Company’s 2026 Form 10-K.
The Company's centralized manufacturing and support organizations, including global operations and certain administrative functions, provide support to its operating segments. Costs incurred by these organizations, as well as depreciation and amortization and equity-based compensation expense are allocated to cost of goods sold as overhead. Consequently, depreciation and amortization and equity-based compensation expense are not independently identifiable components within the segment’s results and, therefore, are not provided.
With the exception of goodwill, the Company does not identify assets by operating segment. Consequently, the chief operating decision maker does not regularly review or receive discrete asset information by operating segment.
The table below reconciles the Company's reportable segment to income before income taxes:
| Three Months Ended | |||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | ||||||||||||||||||||||
| (In thousands) | |||||||||||||||||||||||
| Revenue | $ | 8,219,418 | $ | 5,324,173 | |||||||||||||||||||
| Installation and warranty expense | 234,051 | 141,475 | |||||||||||||||||||||
| Other cost of goods sold (COGS) (1) | 3,532,885 | 2,410,985 | |||||||||||||||||||||
| Segment COGS | 3,766,936 | 2,552,460 | |||||||||||||||||||||
| Segment gross margin | 4,452,482 | 2,771,713 | |||||||||||||||||||||
| Reconciliation to consolidated gross margin | |||||||||||||||||||||||
| All other COGS | 153,629 | 86,834 | |||||||||||||||||||||
| Gross margin | 4,298,853 | 2,684,879 | |||||||||||||||||||||
| Research and development | 666,398 | 576,446 | |||||||||||||||||||||
| Selling, general, and administrative | 348,728 | 279,345 | |||||||||||||||||||||
| Other income (expense), net | 28,493 | 30,074 | |||||||||||||||||||||
| Income before income taxes | $ | 3,312,220 | $ | 1,859,162 | |||||||||||||||||||
(1)Other COGS is primarily comprised of the capitalized cost of inventory sold, including both direct and indirect costs, but excludes installation and warranty expense and those items not allocated to the segment.
Lam Research Corporation 2027 Q1 10-Q 15
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Documents To Review In Connection With Management’s Discussion and Analysis Of Financial Condition and Results Of Operations
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and accompanying Notes to unaudited Condensed Consolidated Financial Statements included in Part I, Item I of this Form 10-Q and the audited Consolidated Financial Statements and accompanying Notes to Consolidated Financial Statements and MD&A included in our 2026 Form 10-K.
EXECUTIVE SUMMARY
Lam Research Corporation is a global supplier of innovative wafer fabrication equipment and services to the semiconductor industry. We have built a strong global presence with core competencies in areas like nanoscale manufacturing enablement, chemistry, plasma and fluidics, advanced systems engineering, and a broad range of operational disciplines. Our products and services are designed to help our customers build smaller and better performing devices that are used in a variety of electronic products, including mobile phones, personal computers, cloud and enterprise servers, wearables, automotive vehicles, and data storage devices.
Our customer base includes leading semiconductor memory, foundry, and integrated device manufacturers that make products such as non-volatile memory, dynamic random-access memory, and logic devices. Their continued success is part of our commitment to driving semiconductor breakthroughs that define the next generation. Our core technical competency is integrating hardware, process, materials, software, and process control, enabling results on the wafer.
Semiconductor manufacturing, our customers’ business, involves the fabrication of multiple dies or integrated circuits on a wafer. This involves the repetition of a set of core processes and can require hundreds of individual steps. Fabricating these devices requires a sequence of highly sophisticated process technologies to integrate an increasing array of new materials with precise control at the atomic scale. Along with meeting technical requirements, wafer processing equipment must deliver high productivity and be cost-effective.
Demand for electronic systems supporting artificial intelligence, cloud infrastructure, communications, automotive, industrial and other intelligent systems is driving the need for high performance, energy efficient and highly integrated semiconductor devices. To meet these requirements, semiconductor manufacturers are adopting vertical scaling approaches, including three-dimensional (“3D”) architecture, more sophisticated patterning schemes, new materials, and advanced integration approaches, as traditional two-dimensional scaling is becoming more challenging. These technology inflections are increasing manufacturing complexity and precision requirements in the production of semiconductors driving demand for our advanced semiconductor fabrication technologies and services.
We believe we are in a strong position with our leadership and expertise in deposition, etch, and clean markets to facilitate some of the most significant innovations in semiconductor device manufacturing. Our Customer Support Business Group provides products and services to maximize installed equipment performance, predictability, and operational efficiency. Several factors create opportunities for sustainable differentiation for us: (i) our focus on research and development, with several ongoing programs relating to sustaining engineering, product and process development, and concept and feasibility; (ii) our ability to effectively leverage cycles of learning from our broad installed base; (iii) our collaborative focus with semi-ecosystem partners, including our close-to-customer focus; (iv) our ability to identify and invest in the breadth of our product portfolio to meet technology inflections; and (v) our focus on delivering our multi-product solutions with a goal to enhance the value of Lam’s solutions to our customers.
Wafer fabrication equipment investments have continued to grow in 2026 with the AI market driving higher semiconductor industry spending across both the memory and non-memory market segments. Over the longer term, we believe that secular demand for semiconductors, combined with technology inflections in our industry, including 3D device scaling, multiple patterning, process flow, and advanced packaging chip integration, will drive sustainable growth and lead to an increase in the market opportunities for our products and services in the deposition, etch, and clean businesses. However, these trends remain subject to volatility in the semiconductor industry environment from trade restrictions and tariffs, as well as the risks, uncertainties, and other factors discussed in Part II, Item 1A, “Risk Factors,” which have had, and in the future may have, a negative impact on our revenue and operating margin.
Lam Research Corporation 2027 Q1 10-Q 16
The following table summarizes certain key financial information for the periods indicated below:
| Three Months Ended | |||||||||||||||||
| September 27, 2026 | June 28, 2026 | ||||||||||||||||
| (in thousands, except per share data and percentages) | |||||||||||||||||
| Revenue | $ | 8,219,418 | $ | 6,722,238 | |||||||||||||
| Gross margin | $ | 4,298,853 | $ | 3,478,740 | |||||||||||||
| Gross margin as a percent of total revenue | 52.3 | % | 51.7 | % | |||||||||||||
| Total operating expenses | $ | 1,015,126 | $ | 965,252 | |||||||||||||
| Net income | $ | 2,753,138 | $ | 2,277,282 | |||||||||||||
| Diluted net income per share | $ | 2.19 | $ | 1.81 |
In the three months ended September 27, 2026 (the “September 2026 quarter”), revenue increased 22% compared to the three months ended June 28, 2026 (the “June 2026 quarter”), driven by strong customer demand for semiconductor equipment systems from customers within the foundry and memory market segments. The increase in gross margin as a percentage of revenue in the September 2026 quarter compared to the June 2026 quarter was mainly attributable to favorable customer and product mix. The increase in operating expenses in the September 2026 quarter compared to the June 2026 quarter was primarily driven by higher incentive compensation due to increased profitability as well as incremental headcount.
Our cash, cash equivalents, and restricted cash balances increased to $7.45 billion at the end of the September 2026 quarter compared to $5.60 billion at the end of the June 2026 quarter. This increase was primarily the result of $3.50 billion of cash generated from operating activities, partially offset by $1.02 billion of share repurchases, including net share settlement of employee stock-based compensation and excise tax; $325.4 million of dividends paid to stockholders; and $257.7 million of capital expenditures. Employee headcount as of September 27, 2026 was approximately 24,300.
RESULTS OF OPERATIONS
Revenue
We generate revenue primarily through the sale and service of semiconductor manufacturing equipment. Demand for our products and services is driven by customers’ investments in wafer fabrication capacity, technology advancement, and installed base support. We present revenue on a disaggregated basis to differentiate between systems revenue and customer support-related revenue. Systems revenue includes sales of new leading-edge equipment in deposition, etch, clean, and other wafer fabrication markets. Customer support-related revenue includes sales of customer services, spares, upgrades, and non-leading-edge equipment from the Company’s Reliant® product line.
Timing of revenue recognition depends on a number of factors, including customer requirements, resource availability, supply chain conditions, manufacturing capacity, delivery schedules, and other operational considerations.
We present our revenues disaggregated by geographic region based on the location of customers’ facilities to which products were shipped and services were rendered. A significant portion of our revenue is generated outside of the United States.
Lam Research Corporation 2027 Q1 10-Q 17
The following table presents our total revenue and revenue disaggregated by geographic region:
| Three Months Ended | |||||||||||||||||||||||||||||
| September 27, 2026 | June 28, 2026 | September 28, 2025 | |||||||||||||||||||||||||||
| Revenue (in millions) | $ | 8,219 | $ | 6,722 | $ | 5,324 | |||||||||||||||||||||||
| China | 35 | % | 26 | % | 43 | % | |||||||||||||||||||||||
| Korea | 20 | % | 20 | % | 15 | % | |||||||||||||||||||||||
| Taiwan | 18 | % | 27 | % | 19 | % | |||||||||||||||||||||||
| Japan | 9 | % | 9 | % | 10 | % | |||||||||||||||||||||||
| United States | 8 | % | 9 | % | 6 | % | |||||||||||||||||||||||
| Southeast Asia | 6 | % | 5 | % | 5 | % | |||||||||||||||||||||||
| Europe | 4 | % | 4 | % | 2 | % |
The following table presents our revenue disaggregated between systems and customer support-related revenue:
| Three Months Ended | |||||||||||||||||||||||||||||
| September 27, 2026 | June 28, 2026 | September 28, 2025 | |||||||||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||||||||
| Systems revenue | $ | 5,732,907 | $ | 4,249,848 | $ | 3,547,565 | |||||||||||||||||||||||
| Customer support-related revenue and other | 2,486,511 | 2,472,390 | 1,776,608 | ||||||||||||||||||||||||||
| $ | 8,219,418 | $ | 6,722,238 | $ | 5,324,173 | ||||||||||||||||||||||||
Systems revenue increased by $1.48 billion, or 35%, in the September 2026 quarter compared to the June 2026 quarter predominantly driven by increases in foundry as well as memory equipment spending. Customer support-related revenue and other increased slightly in the September 2026 quarter compared to the June 2026 quarter.
Systems revenue increased by $2.19 billion, or 62%, in the three months ended September 27, 2026 compared to the same period in 2025 due to higher levels of semiconductor demand leading to increased investments in both memory and non-memory market segments. Customer support-related revenue and other increased by $709.9 million, or 40%, in the three months ended September 27, 2026 compared to the same period in 2025 primarily due to customer investments in non-leading edge equipment and an increase in spares revenue.
The percentage of leading- and non-leading-edge equipment and upgrade revenue from each of the market segments we serve was as follows:
| Three Months Ended | |||||||||||||||||||||||||||||
| September 27, 2026 | June 28, 2026 | September 28, 2025 | |||||||||||||||||||||||||||
| Foundry | 46 | % | 44 | % | 60 | % | |||||||||||||||||||||||
| Memory | 46 | % | 46 | % | 34 | % | |||||||||||||||||||||||
| Logic/integrated device manufacturing | 8 | % | 10 | % | 6 | % |
The increase in the percentage of foundry market segment revenue for the September 2026 quarter compared to the June 2026 quarter was primarily driven by the timing of mature node investments within the China region. The percentage of foundry market segment revenue decreased and the percentage of memory market segment revenue increased in the three months ended September 27, 2026 compared to the same period in the prior year. During this period both the foundry and memory market segments experienced growth on an absolute dollar basis, with the increase in the memory market segment revenue exceeding that of the foundry market segment.
The deferred revenue balance was $2.66 billion at the end of the September 2026 quarter, which is an increase relative to the balance at the end of the June 2026 quarter of $2.43 billion. The increase in the deferred revenue balance is primarily due to increased sales volume, partially offset by a decrease in customer down payments.
Lam Research Corporation 2027 Q1 10-Q 18
Gross Margin
| Three Months Ended | |||||||||||||||||||||||||||||
| September 27, 2026 | June 28, 2026 | September 28, 2025 | |||||||||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||||||||
| Gross margin | $ | 4,298,853 | $ | 3,478,740 | $ | 2,684,879 | |||||||||||||||||||||||
| Percent of revenue | 52.3 | % | 51.7 | % | 50.4 | % |
Gross margin as a percentage of revenue increased in the September 2026 quarter compared to the June 2026 quarter, driven mainly by favorable customer and product mix.
The increase in gross margin in the three months ended September 27, 2026 compared to the same period in the prior year, was primarily due to favorable changes in product mix, as well as improved efficiencies as a result of higher business volumes.
Research and Development
| Three Months Ended | |||||||||||||||||||||||||||||
| September 27, 2026 | June 28, 2026 | September 28, 2025 | |||||||||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||||||||
| Research & development (“R&D”) | $ | 666,398 | $ | 642,922 | $ | 576,446 | |||||||||||||||||||||||
| Percent of revenue | 8.1 | % | 9.6 | % | 10.8 | % |
We continued to make significant R&D investments in the September 2026 quarter focused on leading-edge deposition, etch, clean, and other semiconductor manufacturing processes. R&D expense in the September 2026 quarter increased compared to the June 2026 quarter primarily driven by increased incentive compensation due to improved profitability and incremental headcount.
R&D expense in the three months ended September 27, 2026 increased compared to the same period in the prior year, primarily from employee-related costs due to increased headcount, increased engineering supplies costs and higher depreciation expense.
Selling, General, and Administrative
| Three Months Ended | |||||||||||||||||||||||||||||
| September 27, 2026 | June 28, 2026 | September 28, 2025 | |||||||||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||||||||
| Selling, general, and administrative (“SG&A”) | $ | 348,728 | $ | 322,330 | $ | 279,345 | |||||||||||||||||||||||
| Percent of revenue | 4.2 | % | 4.8 | % | 5.2 | % |
SG&A expense during the September 2026 quarter increased compared to the June 2026 quarter driven by higher incentive compensation due to improved profitability and incremental headcount and outside service spending, partially offset by a decrease in elective deferred compensation plan-related costs.
SG&A expense in the three months ended September 27, 2026 increased compared to the same period in the prior year, primarily as a result of higher headcount driving an increase in employee-related costs and increased spending for outside services.
Lam Research Corporation 2027 Q1 10-Q 19
Other Income (Expense), Net
Other income (expense), net consisted of the following:
| Three Months Ended | |||||||||||||||||||||||||||||
| September 27, 2026 | June 28, 2026 | September 28, 2025 | |||||||||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||||||||
| Interest income | $ | 49,849 | $ | 36,465 | $ | 63,930 | |||||||||||||||||||||||
| Interest expense | (36,762) | (34,203) | (42,472) | ||||||||||||||||||||||||||
| Gains on deferred compensation plan-related assets, net | 12,870 | 61,325 | 23,088 | ||||||||||||||||||||||||||
| Foreign exchange gains (losses), net | 3,889 | (15,464) | (5,534) | ||||||||||||||||||||||||||
| Other, net | (1,353) | (6,469) | (8,938) | ||||||||||||||||||||||||||
| $ | 28,493 | $ | 41,654 | $ | 30,074 | ||||||||||||||||||||||||
Interest income increased in the September 2026 quarter compared to the June 2026 quarter, primarily due to both higher cash balances and higher interest rates. Interest income decreased in the three months ended September 27, 2026 compared to the same period in the prior year, primarily due to lower interest rates.
Interest expense was flat in the September 2026 quarter compared to the June 2026 quarter. Interest expense decreased in the three months ended September 27, 2026 compared to the same period in the prior year primarily due to the maturity of $750 million of the Company’s senior notes in March 2026.
The changes in the gains on deferred compensation plan-related assets, net were driven by fluctuations in the fair market value of the underlying funds for all periods presented.
Foreign exchange fluctuations were primarily due to currency movements against portions of our unhedged balance sheet exposures for all periods presented.
The variation in other, net was primarily driven by the changes in fair value of our equity investments and charitable contributions for all periods presented.
Income Tax Expense
Our provision for income taxes and effective tax rate for the periods indicated were as follows:
| Three Months Ended | |||||||||||||||||||||||||||||
| September 27, 2026 | June 28, 2026 | September 28, 2025 | |||||||||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||||||||
| Income tax expense | $ | 559,082 | $ | 277,860 | $ | 290,502 | |||||||||||||||||||||||
| Effective tax rate | 16.9 | % | 10.9 | % | 15.6 | % |
The increase in the effective tax rate for the September 2026 quarter compared to the June 2026 quarter was primarily due to an increase in Net Controlled Foreign Corporation Tested Income (“NCTI”) tax rate, the change in level and proportion of income in higher and lower tax jurisdictions, the income tax expense from a change in U.S. tax law in the September 2026 quarter, and the recognition of previously unrecognized tax benefits from lapses of statutes of limitation in the June 2026 quarter.
The increase in the effective tax rate for the three months ended September 27, 2026 compared to the same period in the prior year was primarily due to an increase in NCTI tax rate, and the change in level and proportion of income in higher and lower tax jurisdictions in the three months ended September 27, 2026, partially offset by the tax expense associated with the revaluation of deferred taxes due to changes in the U.S. taxation of non-U.S. income under the One Big Beautiful Bill Act (“OBBBA”) in the three months ended September 28, 2025.
International revenues account for a significant portion of our total revenues, such that a material portion of our pre-tax income is earned outside the United States. International pre-tax income is generally taxable in the United States at a lower effective tax rate than the federal statutory tax rate. Please refer to Note 7: Income Taxes to our Consolidated Financial Statements in Part II, Item 8 to our 2026 Form 10-K for additional information.
We re-evaluate uncertain tax positions on a quarterly basis. This evaluation is based on factors including, but not limited to, changes in facts or circumstances, changes in tax law, effectively settled issues under audit, and new audit activity. Any change in recognition or measurement would result in the recognition of a tax benefit or an additional charge to the tax provision.
Lam Research Corporation 2027 Q1 10-Q 20
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
There have been no material changes to our critical accounting policies and estimates to those disclosed in “Critical Accounting Policies and Estimates” in Part II, Item 7 of our 2026 Form 10-K.
Recent Accounting Pronouncements
See Note 2 - Recent Accounting Pronouncements, of our Condensed Consolidated Financial Statements, included in Part 1, Item 1 of this Form 10-Q for details of any recently adopted or effective accounting pronouncements.
Updates Not Yet Effective
In November 2024, the Financial Accounting Standards Board (“FASB”) issued ASU 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,” which requires disaggregation of certain expenses in the notes to the financial statements to provide enhanced transparency into the expense captions presented on the face of the income statement. In January 2025, the FASB issued ASU 2025-01 which clarified the effective date for entities that do not have an annual reporting period that ends on December 31. The guidance is effective for annual periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is required to adopt this standard in fiscal year 2028 for the annual reporting period ending June 25, 2028 either (1) prospectively to financial statements issued for reporting periods after the effective date or (2) retrospectively to any or all prior periods presented in the financial statements. The Company will apply the guidance prospectively and is currently in the process of evaluating the impact of adoption on its Consolidated Financial Statements.
In December 2025, the FASB issued ASU 2025-10, “Accounting for Government Grants Received by Business Entities,” which introduces guidance for recognizing, measuring, and presenting government grants, addressing diversity in practice. The guidance is effective for annual reporting periods beginning after December 15, 2028, and interim reporting within those annual reporting periods, with early adoption permitted. The Company is required to adopt this standard in the first quarter of fiscal year 2030. The Company does not expect the adoption of ASU 2025-10 to have an impact on its Consolidated Financial Statements.
LIQUIDITY AND CAPITAL RESOURCES
Total gross cash, cash equivalents, and restricted cash balances were $7.45 billion at September 27, 2026 compared to $5.60 billion as of June 28, 2026. The increase was primarily driven by cash generated from operating activities totaling $3.50 billion, partially offset by $1.02 billion of share repurchases, including net share settlement on employee stock-based compensation and excise tax; $325.4 million in dividends paid; and $257.7 million in capital expenditures.
Cash Flows from Operating Activities
Net cash provided by operating activities of $3.50 billion and $1.78 billion during the three months ended September 27, 2026 and September 28, 2025, respectively, consisted of:
| Three Months Ended | ||||||||
| September 27, 2026 | September 28, 2025 | |||||||
| (in thousands) | ||||||||
| Net income | $ | 2,753,138 | $ | 1,568,660 | ||||
| Non-cash charges: | ||||||||
| Depreciation and amortization | 122,072 | 101,644 | ||||||
| Equity-based compensation expense | 114,696 | 97,241 | ||||||
| Deferred income taxes | (55,300) | (62,875) | ||||||
| Changes in operating asset and liability accounts | 535,413 | 76,184 | ||||||
| Other | 27,633 | (1,890) | ||||||
| $ | 3,497,652 | $ | 1,778,964 | |||||
Changes in operating asset and liability accounts, net of foreign exchange impact, in the three months ended September 27, 2026 included the following sources of cash: increases in accrued expenses and other liabilities of $832.7 million, accounts payable of $289.8 million and deferred gross profit of $150.2 million. These sources of cash were offset by the following uses of cash: increases in accounts receivable of $342.1 million, inventory of $311.3 million, and prepaid expenses and other current assets of $83.9 million.
Changes in operating asset and liability accounts, net of foreign exchange impact, in the three months ended September 28, 2025 included the following sources of cash: decreases in inventory of $189.8 million and prepaid expenses and other current assets of $30.2 million, and increases in deferred gross profit of $80.9 million, accrued expenses and other liabilities of $25.2 million, and
Lam Research Corporation 2027 Q1 10-Q 21
accounts payable of $5.1 million. These sources of cash were offset by the following uses of cash: increases in accounts receivable of $255.0 million.
The increase of $1.72 billion in net cash provided by operating activities during the three months ended September 27, 2026 compared to the three months ended September 28, 2025 was primarily due to an increase in net income, as well as, changes in operating assets and liabilities, described above.
Cash Flows from Investing Activities
Net cash used for investing activities during the three months ended September 27, 2026 and September 28, 2025 was $267.0 million and $186.0 million, respectively, primarily consisting of capital expenditures for manufacturing capacity and lab infrastructure investments.
Cash Flows from Financing Activities
Net cash used for financing activities during the three months ended September 27, 2026 was $1.38 billion, primarily consisting of $1.02 billion in treasury stock repurchases, including net share settlement on employee stock-based compensation and excise tax, $325.4 million in dividends paid, and $34.5 million of principal payments on debt instruments and debt issuance costs, primarily finance lease-related.
Net cash used for financing activities during the three months ended September 28, 2025 was $1.28 billion, primarily consisting of $975.8 million in treasury stock repurchases, including net share settlement on employee stock-based compensation and excise tax and $292.0 million in dividends paid.
The increase of $100.7 million in net cash used for financing activities during the three months ended September 27, 2026 compared to the three months ended September 28, 2025 was primarily due to incremental share repurchase activity with the execution of $1.00 billion of accelerated share repurchase agreements with two financial institutions in the September 2026 quarter and the increase in the dividend rate over the same period.
Liquidity
Given that the semiconductor industry is highly competitive and has historically experienced rapid changes in demand, we believe that maintaining sufficient liquidity reserves is important to support sustaining levels of investment in R&D and capital infrastructure. Anticipated cash flows from operations based on our current business outlook, combined with our current levels of cash and cash equivalents as of September 27, 2026, are expected to be sufficient to support our anticipated levels of operations, investments, debt service requirements, capital expenditures, capital redistributions, and dividends through at least the next twelve months. However, factors outside of our control, including uncertainty in the global economy and the semiconductor industry, as well as disruptions in credit markets, have in the past, are currently, and could in the future, impact customer demand for our products, as well as our ability to manage normal commercial relationships with our customers, suppliers, and creditors.
Our capital allocation strategy includes a focus to return a portion of our free cash flow to stockholders over time through dividends and share repurchases of Common Stock. Free cash flow is defined as net cash provided by operating activities less cash used for capital expenditures and intangible assets. We expect to fund these capital return activities through future cash provided by operating activities, existing cash and cash equivalents, and/or existing or future available short- and long-term financing.
In the longer term, liquidity will depend to a great extent on our future revenues and our ability to appropriately manage our costs based on demand for our products and services. While we have substantial cash balances, we may require additional funding and need or choose to raise the required funds through borrowings or public or private sales of debt or equity securities. We believe that, if necessary, we will be able to access the capital markets on terms and in amounts adequate to meet our objectives. However, domestic and global macroeconomic and political conditions could cause disruptions to the capital markets and otherwise make any financing more challenging, and there can be no assurance that we will be able to obtain such financing on commercially reasonable terms or at all.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes to our quantitative and qualitative disclosures about market risk set forth in Part II, Item 7A of our 2026 Form 10-K filed with the SEC on August 7, 2026.
Lam Research Corporation 2027 Q1 10-Q 22
Item 4. Controls and Procedures
Management’s Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to comply with Rules 13a-15 and 15d-15 of the Exchange Act.
In designing and evaluating the disclosure controls and procedures, management, including the Chief Executive Officer and Chief Financial Officer, recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Accordingly, our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives.
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 27, 2026. Based upon that evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Lam Research Corporation 2027 Q1 10-Q 23
PART II. OTHER INFORMATION
ITEM 1. Legal Proceedings
Please refer to the subsection entitled “Legal Proceedings” within Note 12 “Commitments and Contingencies," to our Condensed Consolidated Financial Statements in this quarterly report on Form 10-Q.
Item 1A. Risk Factors
In addition to the other information in this Form 10-Q, the following risk factors should be carefully considered in evaluating us and our business because the occurrence of any of these factors could materially and adversely affect our business, results of operations, financial condition, and price of our Common Stock, and they could cause our actual results to differ materially from those contemplated in any forward-looking statements. Some of the factors, events, and contingencies discussed below may have occurred in the past, but the disclosures below are not representations as to whether or not the factors, events, or contingencies have occurred in the past and instead reflect our beliefs and opinions as to the factors, events, or contingencies that could materially and adversely affect us in the future. The risks and uncertainties described below are not the only ones we face. Our operations could also be affected by factors, events, or uncertainties that are not presently known to us or that we currently do not consider to present a material risk to us and our business. Therefore, the following discussion of risk factors should not be considered a complete statement of all the potential risks or uncertainties that we face. No priority or significance is intended by, nor should be attached to, the order in which the risk factors appear.
INDUSTRY AND CUSTOMER RISKS
We Depend on Creating New Products and Processes and Enhancing Existing Products and Processes for Our Success; Consequently, We Are Subject to Risks Associated with Rapid Technological Change
Rapid technological changes in semiconductor manufacturing processes subject us to increased pressure to develop technological advances that enable those processes. We believe that our future success depends in part upon our ability to develop and offer new products with improved capabilities and to continue to enhance our existing products. If new products or existing products have reliability, quality, design, or safety problems, our performance may be impacted by reduced orders, higher manufacturing costs, delays in acceptance of and payment for new products, additional service and warranty expenses, and loss of market share. If we are unable to develop and manufacture products successfully, or the products that we introduce fail in the marketplace, our business, results of operations, and financial condition could be materially and adversely affected. For more than 25 years, the primary driver of technology advancement in the semiconductor industry has been to shrink the lithography that prints the circuit design on semiconductor chips. That driver could be approaching its technological limit, leading semiconductor manufacturers to investigate more complex changes in multiple technologies in an effort to continue technology development. In addition, the emergence of “big data” and new tools such as machine learning and AI that capitalize on the availability of large data sets is leading semiconductor manufacturers and equipment manufacturers to pursue new products and approaches that exploit those tools to advance technology development. In the face of uncertainty on which technology solutions will become successful, we will need to focus our efforts on developing the technology changes that are ultimately successful in supporting our customers’ requirements. Our failure to develop and offer the correct technology solutions in a timely manner with productive and cost-effective products could adversely affect our business in a material way. Our failure to commercialize new products in a timely manner could result in loss of market share, unanticipated costs, and inventory obsolescence, which would adversely affect our business, results of operations, and financial condition.
In order to develop new products and processes and enhance existing products and processes, we expect to continue to make significant investments in R&D, to investigate the acquisition of products and technologies, to invest in or acquire businesses or technologies, and to pursue joint development relationships with customers, suppliers, or other members of the industry. Our investments and acquisitions may not be as successful as we may expect, particularly in the event that we invest in or acquire product lines and technologies that are new to us. We may find that acquisitions are not available to us, for regulatory or other reasons, and that we must therefore limit ourselves to collaboration and joint venture development activities that do not have the same benefits as acquisitions. Pursuing development through collaboration and/or joint development activities rather than through an acquisition may pose substantial challenges for management, including those related to aligning business objectives; sharing confidential information, intellectual property, and data; sharing value with third parties; and realizing synergies that might have been available in an acquisition but are not available through a joint development project. We must manage product transitions and joint development relationships successfully, as the introduction of new products could adversely affect our sales of existing products and certain jointly developed technologies may be subject to restrictions on our ability to share that technology, which could limit our market for products incorporating those technologies. Future technologies, processes, or product developments, including as a result of adoption of AI, may render our current product offerings obsolete, leaving us with non-competitive products, obsolete inventory, or both. Moreover, customers may adopt new technologies or processes to address the complex challenges associated with next-generation devices, or may adopt new technologies, including those based upon AI, that reduce their reliance on us for process development. This shift could reduce the size of our addressable markets, increase the relative size of markets in which we either do not compete or have relatively low market share, or reduce our competitiveness within the markets in which we do compete.
Lam Research Corporation 2027 Q1 10-Q 24
We Face a Challenging and Complex Competitive Environment
We face significant competition from multiple competitors, and our competitors may be able to develop products or services comparable or superior to those we offer or may adapt more quickly to new technologies or evolving customer requirements. In particular, while we continue to develop products and services that we believe will address future customer requirements, we may fail in a timely manner to identify those future customer requirements, to devote appropriate resources to developing products or services to address those requirements, or to complete the development or introduction of these additional products or services successfully, or these products or services may not achieve market acceptance or be competitive. Accordingly, competition may intensify, and we may be unable to continue to compete successfully in our markets, which could have a material adverse effect on our revenues, results of operations, and financial condition.
With increased consolidation efforts in our industry, as well as the emergence and strengthening of new, regional competitors and the impact of AI, we may face increasing competitive pressures. Other companies continue to develop systems and/or acquire businesses and products that are competitive to ours and may introduce new products, product capabilities, or services that may affect our ability to sell and support our existing or new products. We face a greater risk if our competitors enter into strategic relationships with leading semiconductor manufacturers covering products and services addressing applications similar to those we sell or may develop products or services for, as this could adversely affect our ability to sell products or services to those manufacturers for thos
Showing the first 8K of 103K characters. Open the full section
Item 5. Other Information
Rule 10b5-1 and Non-Rule 10b5-1 Trading Arrangements
During the Company’s fiscal quarter ended September 27, 2026, none of the Company’s directors or officers adopted or terminated a trading arrangement for the purchase or sale of the Company’s Common Stock that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a “Rule 10b5-1 Trading Arrangement”) or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
Lam Research Corporation 2027 Q1 10-Q 39
Item 6. Exhibits
| Exhibit Number | Description | ||||
| 31.1 | Rule 13a-14(a)/15d-14(a) Certification (Principal Executive Officer) | ||||
| 31.2 | Rule 13a-14(a)/15d-14(a) Certification (Principal Financial Officer) | ||||
| 32.1 | Section 1350 Certification (Principal Executive Officer) | ||||
| 32.2 | Section 1350 Certification (Principal Financial Officer) | ||||
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | ||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | ||||
Lam Research Corporation 2027 Q1 10-Q 40
LAM RESEARCH CORPORATION
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
| Date: | October 22, 2026 | LAM RESEARCH CORPORATION (Registrant) | |||||||||
| /s/ Douglas R. Bettinger | |||||||||||
| Douglas R. Bettinger | |||||||||||
| Executive Vice President and Chief Financial Officer | |||||||||||
| (Principal Financial Officer) |
Lam Research Corporation 2027 Q1 10-Q 41